Brigatinib (BRG) versus crizotinib (CRZ) in Asian versus non-Asian patients (pts) in the phase III ALTA-1L trial.
Year: 2019
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Myung-Ju Ahn, HyeRyun Kim, James Chih-Hsin Yang, Ji-Youn Han, Jong Seok Lee, Maximilian J. Hochmair, Jacky Yu-Chung Li, Gee-Chen Chang, Ki Hyeong Lee, Cesare Gridelli, Rosario Garcia Campelo, Angelo Delmonte, Dong-Wan Kim, David Kerstein, Quanhong Ni, Pingkuan Zhang, Sanjay Popat, D. Ross Camidge
Institutions: Samsung Medical Center, Sungkyunkwan University, Yonsei University, Severance Hospital, Yonsei University Health System, National Taiwan University, National Cancer Center, Seoul National University Bundang Hospital, Ludwig Boltzmann Institute for Lung Health, Taichung Veterans General Hospital, National Yang Ming University, Chungbuk National University, Chungbuk National University Hospital, Azienda Ospedaliera S.Giuseppe Moscati, Complexo Hospitalario Universitario A Coruña, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Seoul National University Hospital, Takeda Oncology (United States), Royal Marsden Hospital, University of Colorado Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2947037568